ing retention in α v β 6 -expressing xenografts (PET and biodistribution studies). However, the relatively rapid radioactive decay of fluorine-18 (half-life T 1/2 [ 18 F] = 110 minutes) effectively limits the useful PET window to approximately 4 to 6 hours (approximately 2 to 3 half-lives). For that reason, we decided to evaluate tracers containing copper-64, another popular PET radioisotope with a nearly seven times longer half-life (T 1/2 [ 64 Cu] = 12.7 hours). 13 Monocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 14 and cross-bridged 4,11-bis(carboxymethyl)-1, 4,8,11-tetraazabicyclo[6.6.2] hexadecane (CB-TE2A) 15, 16 were chosen as chelators for [ 64 Cu]Cu 2+ . DOTA is a readily available, very widely used monocyclic chelator for a variety of radiometals. However, it has been shown to be prone to demetallation in vivo, resulting in increased levels of radioactivity in the liver caused by strong binding of the copper to liver proteins (transchelation). 13, 17 Given that cross-bridged (ie, bicyclic) CB-TE2A forms very stable complexes with [ 64 Cu ]Cu 2+ , it has been suggested as a potential alternative to DOTA and other 64 Cu chelators, 16, [18] [19] [20] even though it requires elevated temperatures for [ 64 Cu 64 Cu tracers ([ 64 Cu]Cu-DOTA-1 and [ 64 Cu]Cu-CB-TE2A-1; Figure 1 , Table 1 ). The binding characteristics of FBA-1, DOTA-1, and CB-TE2A-1, as well as the unPEGylated reference compound FBA-A20FMDV2, (FBA-2) toward α v β 6 were first evaluated in vitro (1) using purified integrin α v β 6 (ELISA with FBA-1, FBA-2, DOTA-1, CB-TE2A-1) and (2) using α v β 6 -expressing DX3puroβ6 and α v β 6 -negative control DX3puro cell lines (cell binding assay with radiolabeled compounds). The in vivo pharmacokinetic behavior of the radiolabeled compounds was compared by PET and biodistribution studies in a mouse model bearing paired DX3puroβ6 and DX3puro xenografts.
Materials and Methods

General Information
Solvents and chemicals were purchased from Aldrich (Milwaukee, WI) unless stated otherwise. 9-Fluorenylmethoxycarbonyl (Fmoc)-protected amino acids and coupling reagents were purchased from NovaBiochem (San Diego, CA) or GL Biochem (Shanghai, China). Monodisperse Fmoc-amino-PEGcarboxylic acid and Rink Amide NovaGel HL resin (0.63 mmol/g) were obtained from NovaBiochem (San Diego, CA). Sep-Pak SPE cartridges were obtained from Waters (Milford, MA), and 18 F Trap & Release Columns were purchased from ORTG Inc. (Oakdale, TN). Mass spectrometry analysis was performed using an ABI 4700 matrix-assisted laser desorption ionization time of flight/time of flight (MALDI TOF/TOF) spectrometer (Applied Biosystems, Foster City, CA). The DX3puro and DX3puroβ6 cell lines, recombinant soluble α v β 6 (rsα v β 6 ), and mouse monoclonal anti-α v -antibody (clone P2W7) were generated in the laboratory of J.F.M. and have been described previously. 12 Cells were cultured at 37˚C and 8% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM; Mediatech, Manassas, VA) containing 10% heat-inactivated fetal calf serum. Recombinant soluble α v β 3 was a gift from Genentech (San Francisco, CA). IgG1-κ (clone MOPC 21) and ExtrAvidin-peroxidase conjugate were purchased from Sigma (St. Louis, MO). AlexaFluor488-conjugated goat anti-mouse IgG was obtained from Molecular Probes (Invitrogen, Carlsbad, CA). MaxiSorp 96-well microtiter plates were used for ELISA (Nunc, Rochester, NY). 3,3'-5,5'-Tetramethylbenzidine (TMB) substrate was purchased from Dako (Carpinteria, CA). 18, 22 Thin-layer chromatography (TLC) was used to monitor the 64 Cu-radiolabeling reactions. TLC was performed on silica gel plates (Whatman, Florham Park, NJ) using 10% (wt/v) aqueous ammonium acetate/methanol (1:1 v/v) as eluent.
Reverse-phase high-pressure liquid chromatography (HPLC) was used to purify and analyze the compounds: solvent A, 0.05% trifluoroacetic acid (TFA) in water (v/v); solvent B, acetonitrile. HPLC systems were equipped with both an ultraviolet (UV) absorbance detector (UV 220 nm) and a radioactivity detector (photomultiplier tube [PMT] ). The detectors were connected in series, resulting in a slight difference in retention times observed for radioactive compounds and their corresponding cold standards:
• Analytical HPLC system A: Phenomenex Jupiter 4 µ Proteo 90 Å column (250 × 4.6 mm, 4 µm), solvent B isocratic 9% for 2 minutes, then linear gradient to 81% over 30 minutes, flow rate 1.5 mL/min. • Semipreparative HPLC system B: Phenomenex Jupiter 10 µ Proteo 90 Å (250 × 10 mm, 10 µm), solvent B isocratic 9% for 2 minutes, then linear gradient to 81% over 30 minutes, flow rate 3 mL/min.
• Isocratic HPLC system C: Phenomenex Jupiter 10 µ C18 300 Å (250 × 10 mm, 10 µm), isocratic 35% acetonitrile-0.05% TFA in water (v/v), flow rate 3 mL/min. Cell-labeling solutions and biodistribution samples were analyzed on a Wizard 1470 gamma counter (Perkin-Elmer, Waltham, MA). MicroPET scans were acquired on a Focus120 microPET scanner (Siemens Medical Solutions USA, Malvern, PA), and data were processed with the accompanying ASIpro software.
Solid-Phase Peptide Synthesis
Peptides were synthesized on Rink Amide NovaGel HL resin. Manual synthesis was performed using a threefold excess of amino acids and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)/N,N-diisopropylethylamine (DIPEA) activation with a 2-hour coupling time, followed by 30 minutes of Fmoc deprotection with 20% piperidine in N,N-dimethylformamide (DMF). Fmoc-PEG 28 -COOH (formula weight = 1,544.8) was coupled in an overall ratio of 1.65:1 (Fmoc-PEG 28 -COOH/peptide on resin), split into two 18-hour coupling cycles (1.1:1 and 0.55:1 ratios, respectively).
Nonradioactive FBA or DOTA tris(t-Bu ester) was coupled to the N-terminus of the peptide on solid phase using a threefold excess of the acid and HATU/DIEA activation for 1 hour. CB-TE2A was preactivated 18 with N,N'-diisopropylcarbodiimide (DIC) in the presence of DIEA for 30 minutes at room temperature before being coupled to the peptide on solid phase.
The progress of the coupling reactions was monitored by the ninhydrin-based Kaiser test 23 or the picrylsulfonic acid test. 24 Side-chain protecting groups were removed and the peptides were cleaved off the solid support using TFA/1,2-ethanedithiol/triisopropyl-silane/water 94:2.5:1:2.5 (v/v/v/v). The crude peptides, dissolved in water, were washed three times with diethyl ether before purification on semipreparative HPLC (system B) and characterization using mass spectrometry.
Radiochemical Synthesis of [
18 F]FBA-1 [ 18 F]FBA was prepared according to a published procedure and coupled to the N-terminally deprotected peptide on solid phase as previously described. 12, 21, 25 Briefly, the [
18 F]FBA in DMF (50 µL) was withdrawn into a 1 mL fritted syringe containing the peptide resin (5 mg) swollen in DMF, followed by HATU (5 mg) in DMF (30 µL) and DIEA (10 µL) in DMF (30 µL). The reaction mixture was shaken at room temperature for 30 minutes. The solvent was removed, and the resin was washed with DMF (3 × 0.5 mL) and methanol (3 × 0.5 mL). The TFA cleavage mixture (0.7 mL; TFA/triisopropylsilane/water 95:2.5:2.5 v/v/v) was drawn into the syringe, and the reaction mixture was incubated at 30˚C for 20 minutes. The solution was collected. Following evaporation of the cleavage solvents, the product was purified by semipreparative HPLC (system C). The fractions containing the product were collected, diluted with water to a total volume of 20 mL, and passed through a C18 Sep-Pak cartridge. The product, trapped on the cartridge, was washed with water (5 mL) and eluted with 1% acetic acid in ethanol (v/v). The solvent was removed by a stream of nitrogen and the product was reconstituted in phosphate-buffered saline (PBS), followed by pH adjustment. The specific activity was determined by comparison of the radiotracer with the nonradioactive standard (HPLC, system A). The synthesis was similar to that of [ 64 Cu]Cu-DOTA-1 except the reaction solution was buffered to pH 7.5 to 8.5 and incubated at 90 to 95˚C. Formulation and evaluation (TLC, HPLC) were performed as with [ 64 Cu]Cu-DOTA-1.
In Vitro Experiments
IC 50 values were determined as previously described 12 using competitive ELISA of the nonradioactive compounds FBA-1, DOTA-1, CB-TE2A-1, FBA-2, and the parent peptide A20FMDV2 (2) against biotinylated natural ligands, either biotinylated fibronectin (α v β 6 assays) or vitronectin (α v β 3 assays), in triplicate on microtiter plates. For cell binding experiments, 0.2 µCi aliquots of the radiotracer in 50 µL serum-free DMEM (pH 7.2) was added to the cell suspension (3.75 × 10 6 cells in 50 µL serum-free DMEM) and incubated at room temperature for 1 hour. The assay tubes, pretreated with bovine serum albumin (5% wt/v in PBS) to block nonspecific binding, were regularly agitated to prevent settling of the cells. Following gentle centrifugation, the supernatant was removed and the cells were washed with 0.5 mL serum-free DMEM. The supernatants were combined, and the cells were resuspended in 0.6 mL serum-free DMEM. To determine the fraction of radioactivity bound to cells, levels of radioactivity in the cell suspension and in the supernatants were measured in a gamma counter. For each radiotracer, experiments with DX3puroβ6 and DX3puro cell lines were carried out simultaneously (n ≥ 4/cell line).
In Vivo Experiments
All animal experiments were conducted under a protocol approved by the University of California, Davis, Animal Use and Care Committee. Male athymic mice (nu/nu; Charles River Laboratories, Wilmington, MA) were inoculated subcutaneously on opposite flanks in the shoulder region with 3 × 10 6 DX3puro or DX3puroβ6 cells in 100 µL serum-free DMEM. Cell lines were analyzed by flow cytometry before injection to confirm levels of integrin expression. Food and water were available ad libitum. Imaging was conducted 2 to 4 weeks after injection once tumors had reached a diameter of approximately 0.5 cm.
MicroPET Imaging
The radiotracer (approximately 100-250 µCi) in isotonic solution (150-200 µL) was injected intravenously into the tail vein via a catheter in mice (n = 3/tracer) anesthetized with 3% isoflurane. The animals were placed in a feet-first, prone position on the scanner bed and maintained under 1.5 to 2.0% isoflurane. The body temperature was measured by a rectal probe and maintained with a heating pad, supplemented by a heating lamp. For [
18 F]FBA-1, dynamic 4 × 15-minute scans were acquired starting 15 minutes after injection, followed by single-frame 15-minute scans at 2 and 4 hours after injection. For [ 64 Cu]Cu-DOTA-1 and [ 64 Cu]Cu-CB-TE2A-1, single-frame 15-minute scans were acquired 4 hours after injection. Full body image reconstructions were obtained using a maximum a posteriori algorithm (ASIpro software).
Biodistribution
The radiotracer (approximately 15-30 µCi for the 1-, 2-, and 4-hour time points; 100 µCi for the 12-hour time point) in isotonic solution (150-200 µL) was injected intravenously into the tail vein via a catheter in mice anesthetized with 3% isoflurane. Following a conscious uptake period, the mice were anesthetized (4% isoflurane), sacrificed, and dissected (n = 3/tracer). Organs were rapidly collected, and radioactivity was measured in a gamma counter. Calibrated, decaycorrected radioactivity concentrations are expressed as the percentage of injected dose per gram of tissue (% ID/g).
Statistical Analysis
Data are reported as mean ± SD. Two-tailed Student ttests were performed to evaluate statistical significance, where p < .05 was considered statistically significant.
Results
Nonradioactive Peptides
The compounds were prepared as described and obtained in high purity. The analytic data for the peptides are as follows: FBA-1, HPLC (system A, UV 
In Vitro Evaluation: ELISA
Assays were performed to evaluate the ability of nonradioactive FBA-1, DOTA-1, and CB-TE2A-1 to inhibit binding of biotinylated natural ligands (fibronectin or vitronectin) to the immobilized integrin α v β 6 or the closely related α v β 3 . For comparison, the unPEGylated FBA-2 and the parent peptide A20FMDV2 (2) were included as well. Binding values are listed in Table 1 . For all compounds, the data show IC 50 values in the low nanomolar range for integrin α v β 6 , together with no significant binding (IC 50 >
In Vitro Evaluation: Cell Labeling
The radiolabeled compounds were evaluated in cell binding assays (Figure 2 ). The cell line DX3puroβ6, stably transduced to express α v β 6 , and the paired control line DX3puro, lacking expression of α v β 6 , were analyzed as positive and negative cell lines, respectively. 12 Both lines expressed equal levels of integrin α v β 3 and other integrins. For all tracers, less than 5% of radioactivity bound to the α v β 6 -negative DX3puro cell line. When the tracers were incubated with α v β 6 -positive DX3puroβ6 cells, binding levels of 14% were observed for the unPEGylated FBA-2, whereas the PEGylated tracers [ 
In Vivo Evaluation
The in vivo evaluation of [ 18 F]FBA-1, [ 64 Cu]Cu-DOTA-1, and [ 64 Cu]Cu-CB-TE2A-1 by PET and biodistribution studies was performed using our previously described mouse model 12 bearing paired human xenografts of DX3puroβ6 (α v β 6 positive) and DX3puro (α v β 6 negative) ( Figure 3 and Figure 4 ).
Initial microPET scans obtained 15 to 75 minutes (4 × 15-minute frames), 2 hours, and 4 hours after injection with [ 18 F]FBA-1 (n = 3 animals) showed selective uptake in the α v β 6 -positive over the α v β 6 -negative xenograft (see Figure 3A) , along with renal clearance as the major route of elimination from the body (not shown). The later time points indicated efficient clearance from the kidneys. MicroPET scans for [ 64 Cu]Cu-DOTA-1 and [ 64 Cu]Cu-CB-TE2A-1 obtained 4 hours after injection (see Figure 3 , B and C; n = 3 animals per tracer) also showed preferential Figure 4A) , with α v β 6 -positive/α v β 6 -negative xenograft ratios > 4.5:1 (p < .006). Values for blood, muscle, and liver were low and showed good clearance over the duration evaluated (see Figure 4 , B and C). Clearance from the kidneys (see Figure 4D ) and excretion in the urine were rapid (kidneys: 1 hour, 24.7 ± 4.8% ID/g; 4 hours, 2.7 ± 0.8% ID/g; urine: 1 hour, 231 ± 21% ID/g; 4 hours, 103 ± 110% ID/g).
Uptake values of [ 64 Cu]Cu-CB-TE2A-1, 7.3:1, p = .003). However, the biodistribution studies also confirmed the unexpectedly high and persistent levels (40 to 60% ID/g; see Figure 4D ) of radioactivity in the kidneys for the two 64 Cu tracers. Clearance from blood and muscle was good for both compounds and comparable to the values seen for the 18 F tracer (see Figure 4B ). Whereas [ 64 Cu]Cu-CB-TE2A-1 showed low levels of radioactivity in the liver and gallbladder (see Figure 4C ; 4 hours: 0.25 ± 0.02% ID/g and 1.2 ± 0.3% ID/g, respectively, again similar to those of the 18 F tracer), [ 64 Cu]Cu-DOTA-1 showed higher and, for the liver, increasing levels of radioactivity (liver: 4 hours: 0.93 ± 0.18% ID/g, 12 hours: 1.7 ± 0.1% ID/g, p = .002; gallbladder: 4 hours: 2.7 ± 1.2% ID/g, 12 hours: 3.0 ± 0.6% ID/g, p = not significant).
Discussion
The peptide A20FMDV2 has been recognized as a high-affinity, high-specificity ligand for the integrin α v β 6 12,26 and provides an attractive platform for the development of targeted in vivo imaging tracers. For the present study, solid-phase peptide synthesis and radiolabeling of the 18 F and 64 Cu tracers followed robust protocols, 15, 21, 25 yielding the radiotracers in high radiochemical purity (≥ 99%).
Given that modifications of a peptide such as the Nterminal addition of the prosthetic group and/or PEGylation can potentially influence the targeted binding behavior, the affinities and selectivities for α v β 6 of FBA-1, DOTA-1, and CB-TE2A-1 were first compared with A20FMDV2 (2) 12 and unPEGylated FBA-2 (see Figure 1) . The results obtained by competitive ELISA (see Table 1 ) demonstrated that neither the introduction of the PEG moiety nor the choice of prosthetic group had any significant deleterious effect on binding to purified α v β 6 . All compounds selectively bound to integrin α v β 6 with the same high affinity as the parent A20FMDV2 and exhibited > 1,600-fold selectivity over the closely related integrin α v β 3 . These findings were corroborated by subsequent cell binding studies with the radiotracers using the melanoma cell line DX3puroβ6, stably transfected to express α v β 6 , and its paired control line DX3puro (see Figure 2) PEGylation is known to positively affect the characteristics of biologically important drug or diagnostic molecules. 27, 28 In this cell binding assay, the presence of a small PEG spacer between the prosthetic group and the targeting peptide was also found to have a significant, positive effect on binding to α v β 6 , whereas an additional change of the prosthetic group at the end of the PEG spacer had only a slight effect: Cu]Cu-CB-TE2A-1, respectively. These results highlight the significant differences between α v β 6 captured on microtiter plates and α v β 6 expressed on a cell surface. They underscore the importance of considering the biologic environment early in the development of targeted imaging tracers.
In preliminary studies, [ 18 F]FBA-1 had shown the greatest promise in vivo, combining generally good clearing from nontarget tissues with excellent retention in α v β 6 -expressing xenografts. Besides improved tumor retention, introduction of the PEG moiety also resulted in elevated levels of radioactivity in the kidneys, especially at the early time points, but renal clearing remained efficient (see Figure 4D ): values dropped from 24.7 ± 4.8% ID/g at 1 hour post injection to 2.7 ± 0.8% ID/g at 4 hours postinjection (compared with 3.6 ± 1.4% ID/g and 0.15 ± 0.09% ID/g for [ Cu]Cu-CB-TE2A-1. However, most notably, the 4-hour data for both 64 Cu tracers also revealed high levels of radioactivity in the kidneys. Biodistribution studies subsequently corroborated these observations: uptake in the kidneys was high and persistent ( 13, 29 It is generally understood that glomerular filtration and reabsorption in the proximal tubules (endocytosis and lysosomal metabolism) play key roles in the retention and that different mechanisms may be involved to various degrees for different radiotracers. To reduce trapping of the radiotracer or its metabolites in the tubular cells and thus reduce the radiation dose to the kidney, either the rate of endocytosis needs to be low or exocytosis and subsequent excretion in the urine need to be efficient. 29, 30 In some instances, reducing the positive charge of metal-chelating radiotracers resulted in significantly improved clearance behavior, whereas the correlation was less clear in other studies. 29, 31, 32 When charge effects were evaluated specifically for 64 Culabeled macrocyclic complexes, increased positive formal charges were also found to result in increased kidney accumulation, whereas the related negatively charged or neutral complexes showed better renal clearance. 33 Compared with the high values seen for our 64 Cu tracers, in these studies, kidney uptake of [ 64 Cu]Cu-DOTA was comparatively modest, reaching only 1.26 ± 0.14% ID/organ (2 hours post injection; rat) and dropping to 0.54 ± 0.08% ID/organ 24 hours after injection.
The 64 Cu tracers. Clearly, this assumption in not supported by our observations. Similar, seemingly contradictory results have been reported for charge modifications of some octreotide radiotracers. 13, 29 Anderson and colleagues showed that radiometal chelate-conjugated peptides that bind to cell surface receptors such as somatostatin are taken up intracellularly into lysosomes, and then the compounds are metabolized to radiometal chelate-Nterminal amino acids. 34, 35 These metal chelate-based metabolites are retained in the kidneys, whereas halogenated metabolites are likely effluxed from the kidney cells. Interestingly, PEGylation has been suggested as a general strategy to improve the pharmacokinetics of radiopharmaceuticals and thereby reduce renal retention. 14, 27, 29 Despite the unfavorable renal pharmacokinetics encountered for [ 64 Cu]Cu-DOTA-1 and [ 64 Cu]Cu-CB-TE2A-1, some noteworthy differences were observed for other organs. Most notably, the CB-TE2A tracer was superior to the DOTA tracer with respect to liver uptake (see Figure 4) . Corroborating our initial assumption, only [ 64 Cu]Cu-DOTA-1 showed elevated and increasing levels of radioactivity in the liver. Even though this study was not extended beyond the 12-hour time point, other reports support the assumption that this trend, caused by in vivo transchelation of [ 64 Cu]Cu 2+ , would have continued. 36 Thus, despite the limitations observed here for the 64 Cu chelators in conjunction with A20FMDV2, CB-TE2A has shown encouraging results in other studies, 16, 18, 20 making it a valuable alternative to other 64 Cu chelators for peptide radiotracers.
Conclusion
Peptide radiotracers based on the A20FMDV2 sequence hold promise for targeted detection of the integrin α v β 6 , a cell surface receptor implicated in many aggressive cancers. Three PEGylated A20FMDV2 tracers, [ Cu]Cu-CB-TE2A-1, were compared. In vitro, all three compounds showed excellent selectivity for α v β 6 . ELISA data were equivalent to those of the parent peptide A20FMDV2. Cell binding assays showed 13-to 30-fold preferential binding to α v β 6 -expressing cells over the α v β 6 -negative control, confirming maintained specificity α v β 6 in biologic systems. In vivo, all three tracers also showed similar, preferential uptake for the α v β 6 -expressing xenograft over the α v β 6 -negative control. The use of 64 Cu tracers allowed studies over an extended period of time. 
